FBR & Co lowered shares of Juno Therapeutics Inc (NASDAQ:JUNO) from an outperform rating to a market perform rating in a research note released on Wednesday. They currently have $30.00 target price on the biopharmaceutical company’s stock.

JUNO has been the topic of several other research reports. Zacks Investment Research lowered Juno Therapeutics from a hold rating to a sell rating in a report on Wednesday, October 5th. BTIG Research initiated coverage on Juno Therapeutics in a report on Tuesday, August 30th. They set a sell rating and a $23.00 price objective on the stock. Leerink Swann reaffirmed an outperform rating and set a $45.00 price objective on shares of Juno Therapeutics in a report on Tuesday, September 27th. Standpoint Research initiated coverage on Juno Therapeutics in a report on Thursday, August 25th. They set a buy rating and a $47.00 price objective on the stock. Finally, Maxim Group dropped their price objective on Juno Therapeutics from $80.00 to $50.00 and set a buy rating on the stock in a report on Friday, August 5th. Five research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of Buy and a consensus target price of $43.13.

Analyst Recommendations for Juno Therapeutics (NASDAQ:JUNO)

Shares of Juno Therapeutics (NASDAQ:JUNO) remained flat at $22.56 during trading on Wednesday. 17,580,347 shares of the stock traded hands. The stock’s market capitalization is $2.31 billion. Juno Therapeutics has a 12-month low of $19.41 and a 12-month high of $57.82. The firm’s 50-day moving average is $27.75 and its 200-day moving average is $33.02.

Juno Therapeutics (NASDAQ:JUNO) last posted its earnings results on Wednesday, November 9th. The biopharmaceutical company reported ($0.57) EPS for the quarter, missing the consensus estimate of ($0.52) by $0.05. The company earned $20.80 million during the quarter, compared to analysts’ expectations of $10.98 million. Juno Therapeutics’s revenue was up 1200.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.26) earnings per share. On average, equities research analysts expect that Juno Therapeutics will post ($2.54) EPS for the current year.

In other Juno Therapeutics news, EVP Robert Azelby sold 12,921 shares of the stock in a transaction dated Thursday, November 10th. The shares were sold at an average price of $24.14, for a total value of $311,912.94. Following the completion of the transaction, the executive vice president now directly owns 48,640 shares of the company’s stock, valued at $1,174,169.60. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CEO Hans Edgar Bishop sold 44,000 shares of the stock in a transaction dated Tuesday, September 27th. The shares were sold at an average price of $33.00, for a total transaction of $1,452,000.00. Following the completion of the transaction, the chief executive officer now directly owns 2,490,859 shares of the company’s stock, valued at $82,198,347. The disclosure for this sale can be found here.

Hedge funds and other institutional investors have recently modified their holdings of the stock. BlackRock Group LTD boosted its position in shares of Juno Therapeutics by 15.3% in the first quarter. BlackRock Group LTD now owns 34,653 shares of the biopharmaceutical company’s stock worth $1,320,000 after buying an additional 4,609 shares during the period. State Street Corp boosted its position in shares of Juno Therapeutics by 20.8% in the first quarter. State Street Corp now owns 1,218,468 shares of the biopharmaceutical company’s stock worth $46,412,000 after buying an additional 210,019 shares during the period. Geode Capital Management LLC boosted its position in shares of Juno Therapeutics by 4.2% in the first quarter. Geode Capital Management LLC now owns 423,661 shares of the biopharmaceutical company’s stock worth $16,137,000 after buying an additional 17,205 shares during the period. Creative Planning boosted its position in shares of Juno Therapeutics by 3.1% in the second quarter. Creative Planning now owns 29,740 shares of the biopharmaceutical company’s stock worth $1,143,000 after buying an additional 900 shares during the period. Finally, IBM Retirement Fund bought a new position in shares of Juno Therapeutics during the second quarter worth about $244,000.

COPYRIGHT VIOLATION WARNING: “Juno Therapeutics Inc (JUNO) Lowered to “Market Perform” at FBR & Co” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another publication, it was stolen and republished in violation of US & international trademark and copyright laws. The original version of this news story can be accessed at https://www.thecerbatgem.com/2016/11/24/juno-therapeutics-inc-juno-lowered-to-market-perform-at-fbr-co.html.

About Juno Therapeutics

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company focused on re-engaging the body’s immune system to revolutionize the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

5 Day Chart for NASDAQ:JUNO

Receive News & Stock Ratings for Juno Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc and related stocks with our FREE daily email newsletter.